Drug Profile


Latest Information Update: 27 May 2009

Price : $50

At a glance

  • Originator Repros Therapeutics
  • Class Erectile dysfunction therapies
  • Mechanism of Action Alpha adrenergic receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 31 Oct 2002 Suspended - Phase-II for Erectile dysfunction in USA (PO)
  • 25 Sep 2002 Phase-II clinical trials in Erectile dysfunction in Mexico (PO)
  • 27 Aug 2001 A study has been added to the adverse events and Men's Health therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top